Sanofi SA (SASYn)

Currency in EUR
79.00
0.00(0.00%)
Closed·
SASYn is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
79.0079.00
52 wk Range
72.5688.50
Key Statistics
Prev. Close
79
Open
79
Day's Range
79-79
52 wk Range
72.56-88.5
Volume
50
Average Volume (3m)
4.29K
1-Year Change
-7.6023%
Book Value / Share
58.66
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SASYn Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine’s AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV’574, for treatment of ulcerative colitis and Crohn’s disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Employees
74846
Market
France

Compare SASYn to Peers and Sector

Metrics to compare
SASYn
Peers
Sector
Relationship
P/E Ratio
19.6x18.7x−0.5x
PEG Ratio
0.460.810.00
Price/Book
1.4x1.6x2.6x
Price / LTM Sales
2.1x2.3x3.2x
Upside (Analyst Target)
-26.5%47.4%
Fair Value Upside
Unlock24.6%7.7%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 4.03%
Dividend Yield
-
Industry Median 4.74%
Annualised payout
-
5-Years Growth
-
Growth Streak

Earnings

Latest Release
17/02/2026
EPS / Forecast
-0.67 / --
Revenue / Forecast
12.21B / --
EPS Revisions
Last 90 days

Sanofi (SASYn) Income Statement & Profits

FAQ

What Is the Sanofi (Paris: SASYn) Share Price Today?

The Sanofi stock price today is 79.00 EUR.

What Stock Exchange Does Sanofi (SASYn) Trade On?

Sanofi is listed and trades on the Paris Stock Exchange.

What Is the Ticker (Stock Symbol) for Sanofi?

The stock symbol (also called a 'ticker') for Sanofi is "SASYn."

What Is the Current Sanofi Market Capitalisation?

As of today, Sanofi (Paris: SASYn) market cap is 96.70B EUR.

What Is Sanofi's (SASYn) Earnings Per Share (TTM)?

The Sanofi EPS is currently 4.03 (Trailing Twelve Months).

Is SASYn a Buy or Sell From a Technical Analyst Perspective?

Based on today's Sanofi moving averages and other technical indicators, the daily buy/sell signal for SASYn stock is Sell.

How Many Times Has Sanofi Stock Split?

Sanofi has split 0 times. (See the SASYn stock split history page for full effective split date and price information.)

How Many Employees Does Sanofi Have?

Sanofi has 74846 employees, based on their latest Companies House report.

What is the current trading status of Sanofi (Paris: SASYn)?

As of 25/04/2026, Sanofi (SASYn) is trading at a share price of 79.00 EUR, with a previous close of 79.00 EUR. The stock has fluctuated within a day range of 79.00 EUR to 79.00 EUR, while its 52-week range spans from 72.56 EUR to 88.50 EUR.

Industry Spotlight

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.